Evidence map›Paper›PMID 35243248›Full record

ArticleiScience2022

Immunomodulatory potential of

Nell G Bond, Marissa D Fahlberg, Shan Yu, Namita Rout, Dollnovan Tran, Taylor Fitzpatrick-Schmidt, Lesli M Sprehe, Elizabeth A Scheef, Joseph C Mudd, Robert Schaub and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nell G BondTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Marissa D FahlbergTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Shan YuTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Namita RoutTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Dollnovan TranTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Taylor Fitzpatrick-SchmidtTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Lesli M SpreheTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Elizabeth A ScheefTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Joseph C MuddTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Robert SchaubRGS Consulting, Pelham, NH 03076, USA.
Amitinder KaurTulane National Primate Research Center, Division of Immunology, Covington, LA 70433, USA.
Tulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Resource for Nonhuman Primate Immune ReagentsR24OD010947 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VILLINGER, FRANCOIS J · 2012 to 2025
$4.9M
Role of RhCMV in shaping the SIV proviral landscapeR01AI167644 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI Joseph Christopher Mudd · 2022 to 2026
$4.3M
NKT cells as modulators of AIDS vaccine efficacyR01AI102693 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUR, AMITINDER · 2012 to 2015
$3.2M
Mechanisms and Therapeutic Targeting of CD4 Down regulation in African Green MonkeysR21OD031229 · OD · TULANE UNIVERSITY OF LOUISIANA · PI MUDD, JOSEPH CHRISTOPHER · 2021 to 2022
$611k
Genetically Modified NKT Cells to Target Viral ReservoirsR21AI145642 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI BRAUN, STEPHEN EDWARD, KAUR, AMITINDER · 2019 to 2020
$468k
NIAID NIH HHS R01 AI102693NIAID NIH HHS R01 AI167644NIAID NIH HHS R21 AI145642NIAID NIH HHS U24 AI126683NIH HHS P51 OD011104NIH HHS R21 OD031229NIH HHS R24 OD010947
6 · The paper itself

Abstract

Invariant natural killer T-lymphocytes (iNKT) are unique immunomodulatory innate T cells with an invariant TCRα recognizing glycolipids presented on MHC class-I-like CD1d molecules. Activated iNKT rapidly secrete pro-and anti-inflammatory cytokines, potentiate immunity, and modulate inflammation. Here, we report the effects of

Indexed as

Biological sciencesComponents of the immune systemImmunologyTranscriptomics

Identifiers

PMID35243248
PMCPMC8866157
OpenAlexW4210866044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.